45 related articles for article (PubMed ID: 36408869)
1. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
Shen D; Song H; Zhang J; Liao C; Wang Y; Fang M; Tang Y
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e1-e4. PubMed ID: 33661174
[TBL] [Abstract][Full Text] [Related]
3. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
J Clin Oncol; 2023 Apr; 41(11):2043-2053. PubMed ID: 36534942
[TBL] [Abstract][Full Text] [Related]
5. A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.
Kawasoe K; Watanabe T; Yoshida-Sakai N; Yamamoto Y; Kurahashi Y; Kidoguchi K; Ureshino H; Kamachi K; Fukuda-Kurahashi Y; Kimura S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894456
[TBL] [Abstract][Full Text] [Related]
6. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
[TBL] [Abstract][Full Text] [Related]
7. Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.
Lin L; Barkman HJ; Smit EF; de Langen AJ; Steeghs N; Beijnen JH; Huitema ADR
Ther Drug Monit; 2024 Feb; 46(1):73-79. PubMed ID: 37348074
[TBL] [Abstract][Full Text] [Related]
8. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.
Prokoph N; Larose H; Lim MS; Burke GAA; Turner SD
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29601554
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma.
Knörr F; Schellekens KPJ; Schoot RA; Landman-Parker J; Teltschik HM; Förster J; Riquelme A; Huitema ADR; Van Eijkelenburg NKA; Beishuizen A; Zwaan CM; Woessmann W; Van der Lugt J
Haematologica; 2023 May; 108(5):1442-1446. PubMed ID: 36519329
[No Abstract] [Full Text] [Related]
10. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Nakai R; Fukuhara S; Maeshima AM; Kim SW; Ito Y; Hatta S; Suzuki T; Yuda S; Makita S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Clin Case Rep; 2019 Dec; 7(12):2500-2504. PubMed ID: 31893088
[TBL] [Abstract][Full Text] [Related]
11. The Challenges of Crizotinib Treatment in a Child With Anaplastic Large Cell Lymphoma.
Vanheeswijck L; Verlooy J; Van de Vijver E; Bervoets A; Balliauw K; Schepens T; Norga K; van Heerden J
J Pediatr Pharmacol Ther; 2021; 26(6):647-654. PubMed ID: 34421417
[TBL] [Abstract][Full Text] [Related]
12. Frequent detection of genetic aberrations reveals novel pathogenesis and treatment modalities in systemic juvenile xanthogranuloma.
Xu J; Ma H; Yao X; Han X; Wen Y; Wang S; Xu Z; Ma L
Pediatr Investig; 2023 Sep; 7(3):212-215. PubMed ID: 37736360
[No Abstract] [Full Text] [Related]
13. Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
Tanaka M; Miura H; Ishimaru S; Furukawa G; Kawamura Y; Kozawa K; Yamada S; Ito F; Kudo K; Yoshikawa T
Pediatr Rep; 2023 May; 15(2):333-340. PubMed ID: 37368362
[TBL] [Abstract][Full Text] [Related]
14. Observation of Alectinib- and Crizotinib- included chemotherapy in children with ALK-positive anaplastic large cell lymphoma: A single institutional experience.
He Y; Pei K; Zhang H; Wang J; Su X; Gan W; Wang P
Cancer Med; 2023 Mar; 12(6):7182-7188. PubMed ID: 36408869
[TBL] [Abstract][Full Text] [Related]
15. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
Brugières L; Cozic N; Houot R; Rigaud C; Sibon D; Arfi-Rouche J; Bories P; Cottereau AS; Delmer A; Ducassou S; Garnier N; Lamant L; Leruste A; Millot F; Moalla S; Morschhauser F; Nolla M; Pagnier A; Reguerre Y; Renaud L; Schmitt A; Simonin M; Verschuur A; Hoog Labouret N; Mahier Ait Oukhatar C; Vassal G
Eur J Cancer; 2023 Sep; 191():112984. PubMed ID: 37549532
[TBL] [Abstract][Full Text] [Related]
17. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
